The role of biological agents for rheumatoid arthritis: Best evidence and guidelines for clinical decision;Uso de agentes biológicos para o tratamento da artrite reumatóide: Melhores evidências e recomendações para a prática clínica

Revista Brasileira de Medicina

Volumn 62, Issue 4, 2005, Pages 156-165

  Bértolo, Manoel ^a,b   Cicconelli, Rozana ^c   Laurindo, Ieda ^d   Castelar, Geraldo ^c,e   Radominski, Sebastião ^f   Xavier, Ricardo ^g,h,i   Clark, Otávio ^a,b,j   Sasse, Emma Chen ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Sociedade Paulista de Reumatologia ^*  (Germany)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Disciplina de Reumatologia da UERJ

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h Faculdade de Medicina de Shimane Japão   (Japan)

ⁱ HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^j Cidade Universitaria   (Brazil)

more..

Author keywords

Adalimumab; Anti tumoral necrosis factor (anti TNF); Etanercept; Infliximab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

AUTOIMMUNE DISEASE; ETIOLOGY; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MORBIDITY; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 20444496510     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322:1277-89.
2. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol 1981; Rev 3:27-44.
3. Marques Neto JF, Gonçalves HT, Langen LFOB, et al. Estudo multicêntrico da prevalência da AR do adulto em amostras da população brasileira. Rev Bras Reum 1993; 33:169-73.
4. Senna ER, De Barros ALP, Silva EO et al. Prevalence of Rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 2004; 31:594-7.
5. Guyatt G, Rennie D. User's Guide to the Medical Literature - a Manual for Evidence-Based Clinical Practice. 1 ed. Chicago-IL: AMA press; 2002.
6. Centre for Evidence Based Medicine. Oxford University http://minerva.minervation.com/cebm/docs/levels.html. In. Oxford University; 2004.
7. Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J 1999; 117(3):138-9.
8. Clark OA, Castro AA. Searching the Literatura Latino Americana e do Caribe em Ciencias da Saude (LILACS) database improves systematic reviews. Int J Epidemiol 2002; 31(1):112-4.
9. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309(6964):1286-91.
10. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. 2 ed. London: BMJ Books; 2001.
11. Rodrigues-Netto N, Ferreira U, Pompeo ACL, Bretas F, Sadi M, Clark O, et al. Usos e indicações de bloqueadores hormonais no câncer da próstata melhores evidências para a decisão clínica. Campinas, SP: COBEU - Comitê Brasileiro de Estudos em Uro-Oncologia; 2002.
12. Quinn MA, Green MJ, Conaghan P, Emery P. How do you diagnose rheumatoid arthritis early? Best Pract Res Clin Rheumatol 2001; 15(1):49-66.
13. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004; 63(10):1269-75.
14. Berthelot JM, Saraux A, Maugars Y, Prost A, Le Goff P. The nosology-taxonomy of recent-onset arthritis: the experience of early-arthritis clinics. Semin Arthritis Rheum 2001; 30(5):354-65.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3):315-24.
16. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46(2):357-65.
17. Scott DL. The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria. Arthritis Rheum 2002; 46(2):286-90.
18. a edition ed. Pensilvania: Lea & Febiger; 1993.
19. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60(10):924-7.
20. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvien TK, van den Heuvel W. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol 2003; 30(12):2585-9.
21. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44(8):1736-43.
22. Jantti JK, Kaarela K, Luukkainen RK, Kautiainen HJ. Prediction of 20-year outcome at onset of seropositive rheumatoid arthritis. Clin Exp Rheumatol 2000; 18(3):387-90.
23. Berglin E, Lorentzon R, Nordmark L, Nilsson-Sojka B, Rantapaa Dahlqvist S. Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(2):268-75.
24. Paimela L, Palosuo T, Leirisalo-Repo M, Helve T, Aho K. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. Br J Rheumatol 1995; 34(12):1146-50.
25. Belghomari H, Saraux A, Allain J, Guedes C, Youinou P, Le Goff P. Risk factors for radiographic articular destruction of hands and wrists in rheumatoid arthritis. J Rheumatol 1999; 26(12):2534-8.
26. Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995; 34(6):529-34.
27. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 Suppl 1:24-9.
28. Valenzuela-Castano A, Garcia-Lopez A, Perez-Vilches D, Rodriguez-Perez R, Gonzalez-Escribano MF, Nunez-Roldan A. The predictive value of the HLA shared epitope for severity of radiological joint damage in patients with rheumatoid arthritis. A 10 year observational prospective study. J Rheumatol 2000; 27(3):571-4.
29. Wassmuth R, Wagner U. Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification. Rheum Dis Clin North Am 2002; 28(1):17-37.
30. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62(2):120-6.
31. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43(8):1831-5.
32. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003; 30(8):1691-5.
33. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(5):677-80.
34. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62(5):427-30.
35. Huizinga TW, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46(5):1155-9.
36. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001; 40(11):1211-20.
37. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43(7):906-14, 2004.
38. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63(3):221-5.
39. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350(9074):309-18.
40. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4):290-7.
41. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003; 42(1):6-13.
42. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002; 41(2):196-204.
43. van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63(3):274-9.
44. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2):328-46.
45. Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001; 28(11):2409-15.
46. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000(4):CD000959.
47. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2):CD000958.
48. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2):CD000957.
49. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003(1):CD002047.
50. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000(4):CD001461.
51. Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000(4):CD001460.
52. Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, et al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2):CD000520.
53. O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42(8):1691-5.
54. Wells G, Haguenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev 2000(2):CD001083.
55. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21(5 Suppl 31):S154-7.
56. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111(6):446-51.
57. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4):290-7.
58. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004; 63(6):627-33.
59. St Clair EW. Disease-modifying anti-rheumatic drugs. In: Primer on the Rheumatic Diseases. 12th edition ed. Atlanta: The Arthritis Foundation 2001; 599-602.
60. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21(5 Suppl 31):S209-10.
61. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, Suarez-Almazor ME. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999; 26(11):2337-43.
62. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002; 29(8):1631-8.
63. Bathon JM et al. A comparison of etarnecept e methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93.
64. Smolen JS et al. Treatment of early rheumatoid arthritis with infliximabe plus methotrexate or methotrexate alone: preliminary results of ASPIRE Trial. Ann Rheum Dis 2003; 62(Suppl 1):64.
65. Bredveld F. BeST study: How should we use TNF antagonists best in RA? EULAR, 2004.
66. Maini, R.N., et al., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-63.
67. Maini, R., et al., Infliximabe (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet, 1999; 354(9194):1932-9.
68. Lipsky, P.E., et al., Infliximabe and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22):1594-602.
69. Moreland, L.W., et al., Etanercepte therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130(6):478-86.
70. Weinblatt, M.E., et al., A trial of etanercepte, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4):253-9.
71. Bathon, J.M., et al., A comparison of etanercepte and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22):1586-93.
72. Genovese, M.C., et al., Etanercepte versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46(6):1443-50.
73. Klareskog, L., et al., Therapeutic effect of the combination of etanercepte and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410):675-81.
74. Keystone, E.C., et al., Once-weekly administration of 50 mg etanercepte in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50(2):353-63.
75. Weinblatt, M.E., et al., Adalimumabe, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1):35-45.
76. van de Putte, L.B., et al., Efficacy and safety of adalimumabe as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63(5):508-16.
77. Furst, D.E., et al., Adalimumabe, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumabe in Rheumatoid Arthritis). J Rheumatol 2003; 30(12):2563-71.
78. Keystone, E.C., et al., Radiographic, clinical, and functional outcomes of treatment with adalimumabe (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50(5):1400-11.
79. Jiang, Y., et al., A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43(5):1001-9.
80. Cohen, S., et al., Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(3):614-24.
81. Khanna, D., M. McMahon, and D.E. Furst, Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5):307-24.
82. Keane, J., et al., Tuberculosis associated with infliximabe, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098-104.
83. Gomez-Reino, J.J., et al., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8):2122-7.
84. Arthritis Res Ther 2004; 6(Suppl 2):S19-S23
85. Hochberg, M.C., et al., Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumabe, etanercepte, and infliximabe when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl 2:ii13-6.